1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,658 | 0,688 | 20:09 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 14:36 | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 68 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
| Di | Tevogen Bio Inc: Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID | 1 | GlobeNewswire (USA) | ||
| Fr | Tevogen Bio Inc: Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans | 1 | GlobeNewswire (USA) | ||
| 10.09. | Tevogen Bio Inc: Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston | 1 | GlobeNewswire (USA) | ||
| 09.09. | Tevogen Bio Inc: Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection | 73 | GlobeNewswire (Europe) | Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")... ► Artikel lesen | |
| 08.09. | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 2 | Investing.com | ||
| 08.09. | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 148 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to... ► Artikel lesen | |
| 04.09. | Tevogen shares EBV treatment forecast with $3.5 billion revenue potential | 2 | Investing.com | ||
| 04.09. | Tevogen Bio Inc: Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas | 80 | GlobeNewswire (Europe) | The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could... ► Artikel lesen | |
| 03.09. | Tevogen highlights need for SARS-CoV-2 treatments for immunocompromised | 2 | Investing.com | ||
| 03.09. | Tevogen Bio Inc: Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 | 86 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals... ► Artikel lesen | |
| 27.08. | Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure | 104 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under... ► Artikel lesen | |
| 26.08. | Tevogen Bio Inc: Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity | 1 | GlobeNewswire (USA) | ||
| 25.08. | Tevogen Bio Inc: Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions | 204 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding... ► Artikel lesen | |
| 22.08. | Tevogen Bio Inc: Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma | 1 | GlobeNewswire (USA) | ||
| 19.08. | Tevogen Bio Holdings reports Q2 results | 1 | Seeking Alpha | ||
| 19.08. | Tevogen Bio Inc: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum | 159 | GlobeNewswire (Europe) | Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access... ► Artikel lesen | |
| 18.08. | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Local Law Enforcement | 1 | GlobeNewswire (USA) | ||
| 18.08. | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery | 3 | GlobeNewswire (USA) | ||
| 14.08. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
108 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,645 | -2,03 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| AMGEN | 233,55 | -1,83 % | EMA Backs Amgen Drug For Rare Autoimmune Disorder | ||
| NOVAVAX | 7,080 | -3,87 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 472,00 | -3,95 % | Regeneron And Sanofi: CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria | PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,080 | -1,89 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,000 | -13,04 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,250 | -1,24 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,632 | -5,11 % | NurExone Biologic: Jahreshoch & Rekord-Volumen nach News - "STRONG BUY"! | ||
| ARROWHEAD PHARMACEUTICALS | 27,970 | 0,00 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
| XOMA ROYALTY | 32,400 | +3,85 % | XOMA Royalty Corp - 8-K, Current Report | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| PHIO PHARMACEUTICALS | 2,230 | +1,36 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,12 % bei einem Aktienkurs von 0,674 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.